RECRUITINGPhase 1 / Phase 2INTERVENTIONAL
BS01 in Patients With Retinitis Pigmentosa
Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa
About This Trial
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Who May Be Eligible (Plain English)
Who May Qualify:
- Confirmed diagnosis of retinitis pigmentosa
- At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.
Who Should NOT Join This Trial:
- Prior receipt of any AAV gene therapy product
- Large amplitude nystagmus
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Confirmed diagnosis of retinitis pigmentosa
* At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.
Exclusion Criteria:
* Prior receipt of any AAV gene therapy product
* Large amplitude nystagmus
Treatments Being Tested
DRUG
BS01
Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
Locations (1)
New Jersey Retina
Teaneck, New Jersey, United States